The landscape of colorectal cancer (CRC) research is being dramatically reshaped by cutting-edge insights into RNA biology, particularly through the lens of N6-methyladenosine (m6A) RNA modification. This epitranscriptomic mark, the most abundant internal modification in eukaryotic messenger RNA, has emerged as a pivotal regulator of RNA metabolism, influencing diverse cellular processes central to cancer development and progression. Recent explorations into m6A’s role in CRC reveal an intricate orchestration involving its writers, erasers, and readers, which together modulate oncogenic signaling pathways and metabolic reprogramming with significant implications for novel therapeutic strategies.
At the core of m6A regulation are the methyltransferase complexes known as “writers,” chiefly METTL3 and METTL14, which catalyze the addition of methyl groups to specific adenosine residues on target RNAs. These modifications impact RNA stability, splicing, export, and translation efficiency, creating a sophisticated epigenetic layer controlling gene expression. In colorectal cancer, METTL3 exhibits a dualistic role depending on the cellular context, either suppressing invasion by modulating the p38/ERK pathways or promoting tumor progression. METTL14 notably restricts cancer stemness by regulating enzymes like SCD1, underscoring the finely tuned balance m6A writers maintain in tumor biology.
Opposing these writers are the m6A “erasers” such as FTO and ALKBH5, enzymes that remove methyl groups and thus dynamically remodel the epitranscriptome. In CRC, FTO amplifies tumor cell proliferation and glycolytic metabolism by demethylating key transcripts such as PKM2 and HK2, enzymes fundamental to anaerobic energy production—a hallmark of cancer cells. ALKBH5, a more enigmatic player, exhibits context-dependent effects: while it can enhance cancer progression through targets like NEAT1, it also curtails metastasis and modulates immune checkpoints, notably PD-L1, highlighting its complex role in tumor immune evasion.
Completing this regulatory triad are the “readers,” proteins that recognize m6A marks and mediate downstream effects. The IGF2BP family, particularly IGF2BP3, stands out as a marker of poor prognosis and a stabilizer of oncogenic mRNAs including MYC and HK2, thereby promoting tumor growth and metabolic adaptation. YTHDF1 further accelerates translation of critical mRNAs such as GLS, a metabolic enzyme, and its activity correlates with resistance to chemotherapeutic agents like cisplatin. These readers function as crucial links connecting m6A methylation with tumor proliferation, immune modulation, and therapy resistance.
At the signaling level, m6A modification intricately modulates key oncogenic pathways that govern colorectal carcinogenesis. Wnt/β-catenin signaling, a cornerstone of CRC pathogenesis, is potentiated by YTHDF1-mediated translation of Wnt pathway activators like FZD9 and WNT6, driving uncontrolled cellular proliferation. Similarly, attenuation of m6A methylation activates the PI3K/Akt pathway, fostering cell survival and proliferation while influencing sensitivity to ferroptosis, a programmed cell death process related to lipid peroxidation. Moreover, MAPK signaling is influenced through METTL3 and WTAP-dependent m6A modifications, which regulate downstream angiogenic factors like VEGFA, fostering a tumor-friendly microenvironment. Intriguingly, METTL3 also stabilizes p53 mRNA, the guardian of the genome, with its silencing reactivating p53 signaling and resensitizing cells to chemotherapy agents, opening avenues for m6A-targeted interventions.
Beyond signaling, m6A highlights its role as a master integrator of metabolic rewiring in colorectal cancer cells. Glycolysis, the enhanced breakdown of glucose even under aerobic conditions, is tightly regulated by m6A readers like IGF2BP2 that stabilize long non-coding RNAs ZFAS1 and OLA1, potent glycolytic enhancers. The methyltransferase METTL3 boosts glycolysis through stabilization of transcripts for HK2 and the glucose transporter SLC2A1, enabling aggressive tumor growth. Amino acid metabolism, pivotal for biosynthesis and redox balance, is similarly regulated; m6A influences key enzymes such as GLS1, SHMT, and IDO1, directly impacting energy production and immune evasion. Lipid metabolism is no less affected, with ALKBH5-dependent modulation of FABP5 leading to decreased FASN expression and lipid accumulation, subsequently inhibiting mTOR signaling—a key nutrient sensor and growth regulator.
The functional cross-talk between metabolic reprogramming and signaling in CRC is orchestrated through m6A modifications acting as molecular hubs. For example, enhanced glycolysis activates PI3K/Akt signaling, driving proliferation, while alterations in lipid metabolism influence mTOR and Wnt/β-catenin pathways via acetyl-CoA availability. This bidirectional communication facilitated by m6A creates a feedback loop where metabolic state influences signaling cascades and vice versa, emphasizing the complexity of tumor biology and the potential for epitranscriptomic therapies to disrupt these networks.
Despite the exciting advances, significant challenges remain in translating m6A-targeted therapies into the clinic. Most evidence stems from in vitro studies and xenograft models, necessitating validation in organoid systems, spatial transcriptomics, and longitudinal patient cohorts to fully understand spatiotemporal dynamics and functional redundancy among m6A regulators. The development of highly selective inhibitors like the METTL3 antagonist STM2457 holds promise but demands extensive testing in solid tumor models, including CRC, to evaluate efficacy and safety profiles.
In addition, identifying robust biomarkers derived from m6A machinery could revolutionize patient stratification and treatment responsiveness prediction. Proteins such as IGF2BP3 and YTHDF1 have emerged as compelling prognostic indicators, but integrating these markers with metabolic and signaling signatures may yield a multi-dimensional approach to precision oncology in CRC. Efforts to map the complete m6A epitranscriptome and dissect its interactions with immune metabolism are underway, potentially unveiling novel therapeutic targets and combinational treatment strategies.
The convergence of RNA epigenetics with cancer metabolism and signaling heralds a new era in colorectal cancer research, positioning m6A modifications as central players in tumor pathophysiology. By modulating RNA fate and function dynamically, the m6A machinery influences cell proliferation, metastasis, immune escape, and resistance to therapy, unveiling vulnerabilities that could be exploited therapeutically. As research progresses toward clinical translation, m6A represents not only a molecular hallmark but a beacon for tailored interventions and improved patient outcomes.
The future of CRC management may well hinge on the precision targeting of the m6A epitranscriptomic code, integrating advances in molecular biology, pharmacology, and bioinformatics. This approach promises to refine conventional therapies, overcome resistance mechanisms, and ultimately improve survival rates. Continued interdisciplinary collaboration will be vital, with rigorous clinical validation guiding the pathway from bench to bedside in this emerging frontier of cancer treatment.
Subject of Research:
m6A RNA modification and its regulatory roles in colorectal cancer.
Article Title:
m6A RNA Modification in Colorectal Cancer: Regulatory Roles, Oncogenic Signaling, and Metabolic Pathways.
News Publication Date:
29-Mar-2026.
Web References:
Not provided.
References:
Not provided.
Image Credits:
Qin Lu.
Keywords:
Colorectal cancer, m6A modification, epitranscriptomics, METTL3, METTL14, FTO, ALKBH5, IGF2BP, YTHDF1, Wnt/β-catenin, PI3K/Akt, MAPK, p53, metabolic reprogramming, RNA methylation, cancer metabolism, targeted therapy.
